Guilin Pharmaceutical-B (01672.HK) released its interim results, with a net loss attributable to shareholders of 87.951 million yuan, a year-on-year decrease of 32.5%.

Zhijing Finance APP News, GL Pharmtech-B (01672.HK) released its interim results for the six months ending on June 30, 2025. The group achieved a total revenue of RMB 104 million, an increase of 111.4% year-on-year; research and development costs were RMB 147 million, an increase of 10.9% year-on-year; the net loss attributable to equity shareholders of the company was RMB 87.951 million, a decrease of 32.5% year-on-year; and the loss per share was 9.14 cents.